Access is a decision. Adoption is a journey.

A positive national decision does not tell an industry team exactly how local implementation will unfold. The remaining questions may concern workforce, pathway design, procurement, diagnostics or the capacity to follow people up. NEUVIOR is interested in the gap between an access proposition and the practical work needed in a specific setting. That gap deserves its own evidence, rather than being hidden inside a national opportunity estimate.

In development · Intended scope and questions for evaluation

The organisation.
The people around it.

A formulary or service opportunity may depend on local evidence, reliable supply, professional review, delivery resources and a separately authorised commercial arrangement.

The people involved

Manufacturers, marketing-authorisation holders, generic and specialty medicines businesses, suppliers and relevant SMEs.

The dependencies

Medical affairs, market access, regulatory, quality, supply, distribution, procurement and receiving healthcare teams.

What to examine

Source quality, local applicability, implementation requirements, continuity, investment assumptions and the receiving organisation’s priorities.

Explore the ecosystem

An illustrative set of programme relationships. The actual participants, authority, funding and permissions must be established for the defined setting. Explore every organisation perspective.

Describe the work behind the opportunity

An access team may know the eligible population yet have limited evidence about the operational pathway. A provider may understand the pathway but face competing service priorities. A commercial forecast can overlook both perspectives if it assumes eligibility translates directly into adoption. A proposed review would make the implementation sequence visible: what changes, who needs to agree, which resources are required and what evidence would justify the next step in that local context.

Keep national and local evidence separate

NHS England’s medicines procurement function concerns hospital commercial arrangements and supply-chain management (NHS England, n.d.). NHSBSA publishes hospital and community prescribing-cost statistics with defined coverage (NHSBSA, n.d.). These sources can inform a discussion, but neither establishes a particular provider’s capacity or willingness to implement a medicine. Our proposed analysis would distinguish published context from local assumptions and avoid presenting national expenditure as the revenue available to a single supplier.

Understand the incentives around the table

A hospital pharmacy team may need reliable delivery and a workable preparation process. A clinical service may need appointment capacity or monitoring arrangements. A finance team may need the timing of costs and contractual consequences. Industry needs to understand which barrier it can appropriately help address. A useful brief describes these perspectives without assuming that every barrier should be solved by a supplier-funded intervention or that commercial access creates authority over clinical decisions.

An implementation proposition with conditions

A useful output would describe the local delivery conditions under which the proposition could be explored, alongside the facts that remain unconfirmed. It would identify the next appropriate discussion and its purpose. The result should help an industry team approach a provider with a specific, evidence-aware question rather than a national forecast presented as a local opportunity.

Start with one pathway question

A bounded PHARMORIS evaluation could examine a permitted, non-promotional implementation question in one care setting. Inputs might include published guidance, approved pathway descriptions, aggregate service activity and locally confirmed resource assumptions. The comparator would be the existing implementation or access brief. The evaluation would test whether dependencies and uncertainties are clearer, not recommend treatment for individuals or claim a provider has agreed to participate before that agreement exists.

Measure readiness with care

Candidate measures include the completeness of the dependency map, the number of assumptions confirmed or rejected by accountable local reviewers, and the work needed to prepare a decision discussion. These measures concern preparation. They do not demonstrate uptake, clinical benefit or financial return. If a later implementation study is justified, its design should distinguish eligibility, actual access, treatment initiation and sustained delivery, with suitable governance and appropriate outcome definitions.

Avoid a forecast that manufactures certainty

We would pause if available data cannot support the population or pathway being discussed, if local reviewers are absent, or if the output is expected to imply endorsement. A sensitivity analysis should show how different capacity and timing assumptions change the proposition. Where a single missing resource determines feasibility, the next step may be a service discussion rather than a more elaborate commercial model. That is a useful finding, not a failed marketing exercise.

A worthwhile industry discussion

Bring one access question where the national case is clearer than the local implementation route. Explain whose decision is needed, what the current evidence says and which dependency remains unresolved. We can explore whether a bounded review could make the conversation more useful for both industry and the health system. The commercial incentive is an implementation proposition grounded in the realities of delivery, with evidence that can be questioned before resources are committed.

Sources and scope

NHS England | Medicines procurement and supply chain | NHSBSA | Hospital and community prescribing costs

NHS England (n.d.) Medicines procurement and supply chain. Available at: https://www.england.nhs.uk/medicines-2/medicines-value-and-access/medicines-procurement-and-supply-chain/ (Accessed: 14 October 2026).

NHSBSA (n.d.) Hospital and community prescribing costs. Available at: https://www.nhsbsa.nhs.uk/statistical-collections/prescribing-costs-hospitals-and-community-england/prescribing-costs-hospitals-and-community-england-2020-2025 (Accessed: 14 October 2026).

Bring the question
your organisation
needs to move.

Tell us where the programme gets stuck, who is affected and what a worthwhile evaluation would help you decide.

Discuss a PHARMORIS evaluation

An initial conversation should describe the organisational question. Agree the purpose and information requirements before sharing records.

One programme. A whole system of people.

Original NEUVIOR motion explainer · 36 seconds · no audio. The film illustrates intended scope and questions for evaluation. Read the transcript.